Time course of inflammation resolution in patients with frequent exacerbations of chronic obstructive pulmonary disease

Medical Science Monitor

Volumn 20, Issue , 2014, Pages 311-320

  Chang, Chun ^a   Yao, Wanzhen ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

Chronic obstructive; Inflammation; Pulmonary disease; Quality of life

Indexed keywords

BUDESONIDE; C REACTIVE PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; IPRATROPIUM BROMIDE; MYELOPEROXIDASE; PREDNISOLONE; SALBUTAMOL; PEROXIDASE;

AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTERIAL CARBON DIOXIDE TENSION; ARTICLE; ARTIFICIAL VENTILATION; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DISEASE EXACERBATION; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PEAK EXPIRATORY FLOW; PROSPECTIVE STUDY; QUALITY OF LIFE; RESPIRATORY ARREST; TREATMENT DURATION; BRONCHITIS; CHINA; COMPARATIVE STUDY; COMPLICATION; LUNG DISEASES, OBSTRUCTIVE; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RECURRENT DISEASE; TIME;

AGED; BRONCHITIS; C-REACTIVE PROTEIN; CHINA; DYSPNEA; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; INTERLEUKIN-8; LUNG DISEASES, OBSTRUCTIVE; MALE; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE; PEROXIDASE; PROSPECTIVE STUDIES; QUALITY OF LIFE; RECURRENCE; STATISTICS, NONPARAMETRIC; TIME FACTORS;

EID: 84895137418     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.889828     Document Type: Article

References (44)

1. Vestbo J, Hurd SS, Agusti AG et al: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med, 2013; 187: 347-65
2. Hurst JR, Vestbo J, Anzueto A et al: Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med, 2010; 363: 1128-38
3. Tashkin DP: Frequent exacerbations of chronic obstructive pulmonary disease-a distinct phenotype? N Engl J Med, 2010; 363: 1183-84
4. Kanner RE, Anthonisen NR, Connett JE: Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med, 2001; 164: 358-64
5. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA: Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002; 57: 847-52
6. Seemungal TA, Donaldson GC, Paul EA et al: Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 1998; 157: 1418-22
7. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P et al: Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax, 2005; 60: 925-31
8. Garcia-Aymerich J, Farrero E, Felez MA et al: Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax, 2003; 58: 100-5
9. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA: Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax, 2000; 55: 114-20
10. Donaldson GC, Seemungal TA, Patel IS et al: Airway and systemic inflammation and decline in lung function in patients with COPD. Chest, 2005; 128: 1995-2004
11. Groenewegen KH, Dentener MA, Wouters EF: Longitudinal follow-up of systemic inflammation after acute exacerbations of COPD. Respir Med, 2007; 101: 2409-15
12. Drost EM, Skwarski KM, Sauleda J et al: Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax, 2005; 60: 293-300
13. Mackay AJ, Donaldson GC, Patel AR et al: Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to evaluate severity of COPD exacerbations. Am J Respir Crit Care Med, 2012; 185: 1218-24
14. Global Initiative for Chronic Obstructive Lung Disease: Guide to COPD diagnosis, management, and prevention. GOLD, 2006
15. McGregor JC, Rich SE, Harris AD et al: A systematic review of the methods used to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients. Clin Infect Dis, 2007; 45: 329-37
16. Nseir S, Di Pompeo C, Cavestri B et al: Multiple-drug-resistant bacteria in patients with severe acute exacerbation of chronic obstructive pulmonary disease: Prevalence, risk factors, and outcome. Crit Care Med, 2006; 34: 2959-66
17. Quint JK, Donaldson GC, Hurst JR et al: Predictive accuracy of patient-reported exacerbation frequency in COPD. Eur Respir J, 2011; 37: 501-7
18. Anthonisen NR, Manfreda J, Warren CP et al: Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med, 1987; 106: 196-204
19. Niewoehner DE, Erbland ML, Deupree RH et al: Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med, 1999; 340: 1941-47
20. Schembri S, Williamson PA, Short PM et al: Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ, 2013; 346: f1235
21. Bhowmik A, Seemungal TA, Sapsford RJ et al: Comparison of spontaneous and induced sputum for investigation of airway inflammation in chronic obstructive pulmonary disease. Thorax, 1998; 53: 953-56
22. Gleckman R, DeVita J, Hibert D et al: Sputum gram stain assessment in community-acquired bacteremic pneumonia. J Clin Microbiol, 1988; 26: 846-49
23. Louis R, Shute J, Goldring K et al: The effect of processing on inflammatory markers in induced sputum. Eur Respir J, 1999; 13: 660-67
24. Efthimiadis A, Pizzichini MM, Pizzichini E et al: Induced sputum cell and fluid-phase indices of inflammation: comparison of treatment with dithiothreitol vs phosphate-buffered saline. Eur Respir J, 1997; 10: 1336-40
25. Hurst JR, Perera WR, Wilkinson TM et al: Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2006; 173: 71-78
26. Miravitlles M, Espinosa C, Fernández-Laso E et al: Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest, 1999; 116: 40-46
27. Dowson LJ, Guest PJ, Stockley RA: Longitudinal changes in physiological, radiological, and health status measurements in alpha(1)-antitrypsin deficiency and factors associated with decline. Am J Respir Crit Care Med, 2001; 164: 1805-9
28. Papi A, Bellettato CM, Braccioni F et al: Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med, 2006; 173: 1114-21
29. Wedzicha JA, Seemungal TA, MacCallum PK et al: Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost, 2000; 84: 210-15
30. Pant S, Walters EH, Griffiths A et al: Airway inflammation and anti-protease defences rapidly improve during treatment of an acute exacerbation of COPD. Respirology, 2009; 14: 495-503
31. Seemungal TA, Donaldson GC, Bhowmik A et al: Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2000; 161: 1608-13
32. Koutsokera A, Kiropoulos TS, Nikoulis DJ et al: Clinical, functional and biochemical changes during recovery from COPD exacerbations. Respir Med, 2009; 103: 919-26
33. Perera WR, Hurst JR, Wilkinson TM et al: Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J, 2007; 29: 527-34
34. Hospital Episode Statistics UDoH, 2003
35. White AJ, Gompertz S, Bayley DL et al: Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax, 2003; 58: 680-85
36. Hurst JR, Donaldson GC, Wilkinson TM et al: Epidemiological relationships between the common cold and exacerbation frequency in COPD. Eur Respir J, 2005; 26: 846-52
37. Hurst JR, Donaldson GC, Perera WR et al: Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2006; 174: 867-74
38. Proud D, Chow CW: Role of viral infections in asthma and chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol, 2006; 35: 513-18
39. Eickhoff P, Valipour A, Kiss D et al: Determinants of systemic vascular function in patients with stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2008; 178: 1211-18
40. Sin DD, Man SF, Marciniuk DD et al: The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2008; 177: 1207-14
41. Calverley PM, Scott S: Is airway inflammation in chronic obstructive pulmonary disease (COPD) a risk factor for cardiovascular events? COPD, 2006; 3: 233-42
42. Gompertz S, Bayley DL, Hill SL, Stockley RA: Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax, 2001; 56: 36-41
43. Tumkaya M, Atis S, Ozge C et al: Relationship between airway colonization, inflammation and exacerbation frequency in COPD. Respir Med, 2007; 101: 729-37
44. 60 fullerenes on blood chemiluminescence. Med Sci Monit, 2012; 18(2): BR76-83